StreetInsider.com News Articles

Zivo Bioscience transitions to OTCID marketplace

Tue, 12 May 2026 10:09:48 -0400

Zivo Bioscience, Inc. (OTCID: ZIVO) announced that its common stock has transitioned to quotation on the OTCID marketplace. The company began trading on OTCID as of May 11, 2026.

The OTCID marketplace is an OTC Markets tier for companies that publish baseline disclosure and maintain current information through OTC Markets' disclosure systems. The transition allows companies to maintain public trading with streamlined reporting requirements and improved flexibility.

"This transition supports our commitment to transparency and continued access for our shareholders," said John B. Payne, CEO. "Completing OTC Markets' review process and moving to OTCID allows us to focus on advancing our scientific

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace

Tue, 12 May 2026 10:09:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCID: ZIVO) ("ZIVO" or the "Company") announced today that it is transitioning its common stock to quotation on the OTCID marketplace.

Zivo Bioscience began trading on OTCID as of Monday, May 11, 2026.

Transitioning to OTCID is a common step for companies seeking to maintain public trading while aligning with a marketplace that offers streamlined reporting requirements, improved flexibility, and continued visibility for investors. Companies moving to OTCID typically do so to promote continued trading, maintain shareholder access to liquidity, and operate within a disclosure framework that supports their stage of growth and

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace

Tue, 12 May 2026 10:09:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCID: ZIVO) ("ZIVO" or the "Company") announced today that it is transitioning its common stock to quotation on the OTCID marketplace.

Zivo Bioscience began trading on OTCID as of Monday, May 11, 2026.

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace

Tue, 12 May 2026 10:09:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCID: ZIVO) ("ZIVO" or the "Company") announced today that it is transitioning its common stock to quotation on the OTCID marketplace.

Zivo Bioscience began trading on OTCID as of Monday, May 11, 2026.

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace

Tue, 12 May 2026 10:09:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCID: ZIVO) ("ZIVO" or the "Company") announced today that it is transitioning its common stock to quotation on the OTCID marketplace.

Zivo Bioscience began trading on OTCID as of Monday, May 11, 2026.

Form 4 Zivo Bioscience, Inc. For: Apr 17 Filed by: STROME GROUP, INC.

Fri, 24 Apr 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260424/26367686.html

Form 4 Zivo Bioscience, Inc. For: Apr 17 Filed by: STROME GROUP, INC.

Fri, 24 Apr 2026 18:16:00 -0400

si-local-file:///var/storage/secattach/20260424/26367686.html

ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass

Mon, 06 Apr 2026 08:00:00 -0400

Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand

TROY, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTCQB: ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the signing of a manufacturing agreement with Cyanotech Corporation to grow, cultivate and process ZIVO's proprietary algal biomass for its Zivolife™ product line.

ZIVO is advancing Zivolife™ toward commercial applications across animal health, human nutrition and functional ingredients markets. This agreement with Cyanotech, one of the world's most established microalgae producers,

ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass

Mon, 06 Apr 2026 08:00:00 -0400

Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand

ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass

Mon, 06 Apr 2026 08:00:00 -0400

Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand

ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife™ Algal Biomass

Mon, 06 Apr 2026 08:00:00 -0400

Partnership with 40-Year Industry Leader Positions ZIVO to Meet Anticipated Global Commercial Demand

Form EFFECT Zivo Bioscience, Inc.

Thu, 02 Apr 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260402/26262030.html

Form EFFECT Zivo Bioscience, Inc.

Thu, 02 Apr 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260402/26262030.html

Form S-8 POS Zivo Bioscience, Inc.

Tue, 31 Mar 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260331/26244279.html

Form S-8 POS Zivo Bioscience, Inc.

Tue, 31 Mar 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260331/26244279.html

Form 15-12G Zivo Bioscience, Inc.

Tue, 31 Mar 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260331/26244299.html

Form 15-12G Zivo Bioscience, Inc.

Tue, 31 Mar 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260331/26244299.html

Form POS AM Zivo Bioscience, Inc.

Tue, 31 Mar 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260331/26244177.html

Form POS AM Zivo Bioscience, Inc.

Tue, 31 Mar 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260331/26244177.html

Form 8-K Zivo Bioscience, Inc. For: Mar 26

Mon, 30 Mar 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260330/26237471.html

Form 8-K Zivo Bioscience, Inc. For: Mar 26

Mon, 30 Mar 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260330/26237471.html

ZIVO Bioscience Provides Special Letter to Shareholders

Fri, 27 Mar 2026 16:43:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.

Dear Fellow Shareholders,

I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. (“ZIVO” or the “Company”): we intend to deregister the Company’s securities with the Securities and Exchange Commission and cease public reporting. This letter explains the reasoning behind this decision, what it means for shareholders, and how it positions ZIVO for its next phase of growth.

A Decision Made in the

ZIVO Bioscience Provides Special Letter to Shareholders

Fri, 27 Mar 2026 16:43:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.
Dear Fellow Shareholders,
I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. (“ZIVO” or the “Company”): we intend to deregister the Company’s securities with the Securities and Exchange Commission and cease public reporting. This letter explains the reasoning behind this decision, what it means for shareholders, and how it positions ZIVO for its next phase of growth.
A Decision Made in the

ZIVO Bioscience Provides Special Letter to Shareholders

Fri, 27 Mar 2026 16:43:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.
Dear Fellow Shareholders,
I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. (“ZIVO” or the “Company”): we intend to deregister the Company’s securities with the Securities and Exchange Commission and cease public reporting. This letter explains the reasoning behind this decision, what it means for shareholders, and how it positions ZIVO for its next phase of growth.
A Decision Made in the

ZIVO Bioscience Provides Special Letter to Shareholders

Fri, 27 Mar 2026 16:43:00 -0400

TROY, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.
Dear Fellow Shareholders,
I am writing to inform you of a significant and carefully considered decision by the Board of Directors of ZIVO Bioscience, Inc. (“ZIVO” or the “Company”): we intend to deregister the Company’s securities with the Securities and Exchange Commission and cease public reporting. This letter explains the reasoning behind this decision, what it means for shareholders, and how it positions ZIVO for its next phase of growth.
A Decision Made in the